← All Bio-techne CORP filings

Bio-techne CORP DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
TECH
Bio-techne CORP
DEFA14A: BIO-TECHNE Files Definitive Proxy Materials with SEC
BIO-TECHNE Corporation has filed definitive additional proxy soliciting materials with the U.S. Securities and Exchange Commission.
NASDAQ
TECH
Bio-techne CORP
DEF: Bio-Techne Navigates Headwinds, Achieves 5% Organic Growth
Bio-Techne Corporation reported 5% organic revenue growth and $1.2 billion in revenue for fiscal year 2025, alongside strategic portfolio adjustments and enhanced governance practices.
NASDAQ
TECH
Bio-techne CORP
DEFA14A: Bio-Techne Corporation Files Definitive Proxy Statement
Bio-Techne Corporation has filed a definitive proxy statement with the SEC.
NASDAQ
TECH
Bio-techne CORP
DEF 14A: Bio-Techne Appoints Kelderman as CEO, Navigates Dynamic Market with 1% Organic Growth
Bio-Techne's proxy statement highlights a CEO transition, strategic growth initiatives, and a focus on shareholder value amidst a challenging market environment.